▼ FY 2025 Summary Analysis
Annual report ending Dec 31, 2025Overview and Growth
Fiscal 2025 results for AEON Biopharma, Inc. included net loss of $39.22M. Diluted earnings per share were -$3.95, translating the period’s attributable earnings into the amount reported for each diluted share. The per-share result recorded a 105.4% decrease from fiscal 2024 diluted EPS of $72.93. Diluted shares averaged 9.92M; this is the reported share base over which the company’s diluted per-share earnings were spread. At period end, total assets were $5.56M, framing the scale of the company’s operating and financing commitments.Profitability
The reported operating result was an operating loss of $12.80M, reflecting costs that exceeded gross profit. The company ended the period with a net loss of $39.22M, extending the operating result through all remaining items. Negative EBITDA totaled $12.72M, confirming that the earnings deficit remained before depreciation and amortization. The pretax result was a loss of $39.22M, establishing the deficit before tax effects. The company recognized $0.00 of income tax for the period, completing the transition from pretax income to net income. The loss-to-assets relationship was 705.4%, placing the bottom-line deficit against the company’s resource base. The company moved from fiscal 2024 net income of $42.01M to a current net loss of $39.22M.Liquidity and Capital Structure
At period end, the $5.56M asset base was financed through $60.59M of liabilities and -$55.03M of equity. Equity was negative at -$55.03M, meaning liabilities exceeded the residual book value available to shareholders and weakening balance-sheet resilience. At period end, current assets of $3.40M compared with current liabilities of $6.90M, defining the company’s short-term resource position. Current assets covered only 0.49x of current liabilities, so current liabilities exceeded current assets at period end. Cash and equivalents totaled $3.01M, identifying the most liquid reported component available within the broader current-asset balance. Cash and equivalents represented 43.6% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Equity equaled -989.7% of assets, showing the shareholder-capital layer within the company’s balance sheet. The cash-to-assets relationship was 54.1%, comparing reported cash and equivalents with the full positive asset balance. The asset base changed 77.0% from $3.14M in fiscal 2024, leaving current total assets higher year over year.Cash Flow and Earnings Quality
Cash flow from operations was an outflow of $17.31M, showing that operations absorbed cash during the period. The company spent $4.00K on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. Negative free cash flow was $17.31M, leaving a cash deficit after capital spending and reducing financial flexibility. The free-cash-flow deficit equaled 311.4% of total assets, placing the cash shortfall against the company’s resource base. Compared with a $20.29M operating cash outflow in fiscal 2024, the current outflow improved to $17.31M.
Based on the annual report for the fiscal year ending Dec 31, 2025.
Analysis generated .
Fundamentals Hub